ALX Oncology Holdings (ALXO) announced the appointment of Scott Garland as Chairman of the Board and Michael Lichtenstein as General Counsel.

Mr. Garland has extensive leadership experience in the biotechnology industry, and his appointment is expected to bring strategic vision to the board of directors. Meanwhile, Mr. Lisgarten will be responsible for the company's legal affairs and compliance management, strengthening the corporate governance structure. These senior management changes mark the company's efforts to reinforce its governance team to support future business development.